Quantcast

Latest Pemetrexed Stories

2011-06-05 08:00:00

INDIANAPOLIS, June 5, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is alive without their disease worsening, for patients with a specific type of lung cancer called advanced nonsquamous non-small cell lung cancer (NSCLC). "Continuation maintenance"...

2011-05-16 07:10:00

INDIANAPOLIS, May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 30 studies at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., from June 3 - 7, 2011, including results from PARAMOUNT, a Phase III study of an ALIMTA-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer. PARAMOUNT data will be included in the ASCO-sponsored press briefing the...

2011-04-28 15:34:00

BROOMFIELD, Colo., April 28, 2011 /PRNewswire/ -- Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute (ALCMI, pronounced as "Alchemy"). The CASTLE (Collaborative Advanced Stage Tissue Lung Cancer) study is recruiting a minimum of 250 subjects over two years among academic and community medical centers in the United States. The study collects biospecimens and data from lung cancer patients in order to facilitate...

2011-03-07 21:48:35

Scientist finds super-survivors for lung cancer treatment A discovery at University of Colorado Cancer Center shows testing lung cancer on a molecular level can produce new insights into this deadly disease. Cancer Center member D. Ross Camidge, MD, PhD, director of the thoracic oncology clinical program at University of Colorado Hospital (UCH), turned a chance clinical observation into a new field of discovery in lung cancer. In October 2010, Camidge and colleagues published a study in the...

2011-02-28 13:29:37

European Multidisciplinary Conference in Thoracic Oncology news The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show. Dr Tudor Ciuleanu from the Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania, reported this finding from the international TITAN study at the European Multidisciplinary...

2011-02-02 08:42:00

INDIANAPOLIS and PRINCETON, N.J., Feb. 2, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC). (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO ) The randomized, multi-center, open-label Phase III trial,...

2011-01-27 00:02:58

This week, the Mesothelioma Applied Research Foundation, the leading organization funding mesothelioma research and providing patient services, announced the election of new Co-Chairs of its Board of Directors. Washington, DC (Vocus/PRWEB) January 26, 2011 The Mesothelioma Applied Research Foundation (Meso Foundation) announced today the election of Axel Hanauske, MD, PhD and Hanne Mintz as Co-Chairs of the Board of Directors of the Mesothelioma Applied Research Foundation. Dr. Hanauske...

2010-11-15 17:18:00

INDIANAPOLIS, Nov. 15, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that the trial on the validity of the compound patent for Alimta® (pemetrexed for injection) before the U.S. District Court for the District of Delaware ended this afternoon with a ruling from the court that judgment would be entered in Lilly's favor, thereby upholding the patent's validity. The decision came in the case of Eli Lilly and Company et al v. Teva Parenteral...

2010-10-11 14:04:33

Data presented today at the 35th European Society for Medical Oncology Congress Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone. Dr. Miklos Pless, head of medical oncology at the Winterthur Hospital Cancer center in Switzerland, presented the data at the...

2010-10-11 06:30:00

INDIANAPOLIS, Oct. 11 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that its global Phase III trial evaluating ALIMTA® (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO)....


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'